Share Email Print
cover

Proceedings Paper

Phase cancellation system for tumor imaging using targeted fluorescent contrast agents
Author(s): Yu Chen; Lanlan Zhou; Chenpeng Mu; Xavier Intes; Samuel I. Achilefu; Britton Chance
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

Recent developments in receptor specific targeting fluorescent contrast agents can give tumor/tissue contrasts in the excess of 10, and are capable of selectively labeling various pre-cancer/cancer signatures to enhance the sensitivity and specificity of cancer detection [reference: Weissleder et al, Achilefu et al]. We have developed a novel imaging system for fast and accurate localization of fluorescent contrast agent labeled tumor embedded several centimeters inside the highly scattering medium mimicking breast tissue using the phased cancellation configuration (00 and 1800 source-pair) with a goniometric probe. Phantom tests and intratumor injection of fluorescent dye, Indocyanine Green (ICG), have demonstrated the capability of twodimensional localization of tumor labeled with fluorescent contrast agents about 3.0 cm deep within several millimeters enor range. The accuracy of the localization suggests that this system would be helpful to guide the clinical fine-needle biopsy for early detection of breast cancer.

Paper Details

Date Published: 12 September 2002
PDF: 8 pages
Proc. SPIE 4916, Optics in Health Care and Biomedical Optics: Diagnostics and Treatment, (12 September 2002); doi: 10.1117/12.482934
Show Author Affiliations
Yu Chen, Univ. of Pennsylvania (United States)
Lanlan Zhou, Univ. of Pennsylvania (United States)
Chenpeng Mu, Univ. of Pennsylvania (United States)
Xavier Intes, Univ. of Pennsylvania (United States)
Samuel I. Achilefu, Washington Univ. School of Medicine (United States)
Britton Chance, Univ. of Pennsylvania (United States)


Published in SPIE Proceedings Vol. 4916:
Optics in Health Care and Biomedical Optics: Diagnostics and Treatment
Britton Chance; Mingzhe Chen; Gilwon Yoon, Editor(s)

© SPIE. Terms of Use
Back to Top